m6A-modified Mid1 promotes sevoflurane-induced cognitive impairment in neonatal mice by ubiquitin-mediated degradation of Syngap1 Authors: Jian-Jun Shen, Ying-Jie Yang, Ying-Ying Tang, Shuo Yan, Mei-dan Ying, Wen-Hu Chen, Li-Li Xu Published: 2026 ABSTRACT Investigating the cognitive effects of sevoflurane exposure during early development is essential due to its potential long-term neurodevelopmental impacts. This investigation systematically explored the molecular basis of sevoflurane-induced cognitive impairment, with emphasis on m6A RNA modifications and ubiquitin-dependent proteostasis involving Mid1 and Syngap1. Using integrated approaches, including methylated RNA immunoprecipitation sequencing (MeRIP-seq), transcriptomic profiling, neurobehavioural testing and molecular analyses, 2091 m6A methylation sites were identified that were differentially regulated. Mechanistically, Mid1 was found to orchestrate Syngap1 degradation via the ubiquitin–proteasome pathway, establishing a direct link between protein stability control and cognitive outcomes. Behavioural phenotyping demonstrated that Mid1 suppression ameliorated learning and memory deficits in sevoflurane-exposed mice, which was corroborated by improved neuronal viability and attenuated apoptotic signalling in biochemical assays. Epigenetic regulation studies further revealed that the m6A eraser ALKBH5 and the reader YTHDF2 collaboratively modulate Mid1 mRNA stability, thereby contributing to neuropathological progression. Pathway analysis uncovered Mid1–Syngap1 axis-mediated dysregulation of MAPK signalling cascades, proposing this network as a potential therapeutic target. Collectively, the present findings delineated a novel m6A-ubiquitin regulatory circuit centred on Mid1 that drives sevoflurane-associated cognitive dysfunction, offering mechanistic insights for the development of neuroprotective interventions against anaesthesia-related neurotoxicity in paediatric and other at-risk populations. Introduction Sevoflurane is widely used as an anaesthetic in both paediatric and adult populations due to its favourable pharmacokinetic properties, including rapid onset and recovery. Although generally considered safe, accumulating preclinical evidence suggests that sevoflurane exposure during critical neurodevelopmental periods may induce long-term cognitive deficits and behavioural abnormalities1. Rodent studies have shown that neonatal exposure during synaptogenesis (postnatal days 7–10) reduces synaptic density in hippocampal cornu ammonis 1 (CA1) neurons through disruption of dendritic arborization2,3. Previous work has corroborated these findings, demonstrating dose-dependent impairments in cognitive performance, emotional regulation and social behaviours following prolonged sevoflurane exposure (≥3 h)4,5. These observations underscore the necessity to elucidate the molecular mechanisms underlying sevoflurane-induced neurotoxicity. The regulatory role of N6-methyladenosine (m6A) methylation in neural development and inflammatory responses has garnered increasing attention6–8. Dysregulation of m6A modification has been implicated in neurodevelopmental disorders through mechanisms involving altered neural stem cell differentiation and synaptic protein synthesis9,10. In the experimental models used herein, sevoflurane exposure induced 2,091 differentially methylated m6A peaks in hippocampal tissues, with predominant localization in mRNA coding sequences (CDS) and 3’ untranslated regions (3’UTR). This spatial distribution pattern is consistent with established mechanisms wherein CDS-located m6A modifications modulate translational efficiency, while 3’UTR modifications influence mRNA stability. Through integrated analysis of m6A sequencing and RNA sequencing (RNA-seq) datasets, Mid1 emerged as a key candidate gene showing significant upregulation post-sevoflurane exposure. Mid1 encodes an E3 ubiquitin ligase associated with neuronal migration defects in X-linked Opitz G/BBB syndrome11,12. Functional studies revealed that Mid1 knockdown attenuated sevoflurane-induced cognitive deficits, as quantified by improved performance in spatial navigation and associative memory tasks13. Histopathological assessments further demonstrated reduced neuronal apoptosis following Mid1 inhibition. These findings align with recent reports linking Mid1 to Tau phosphorylation regulation via protein phosphatase 2A (PP2A) interaction in neurodegenerative models. Mechanistic investigations identified Syngap1, a synaptic plasticity regulator associated with intellectual disability, as a downstream effector of Mid1. Biochemical analyses suggest that Mid1 modulates Syngap1 ubiquitination, thereby influencing mitogen-activated protein kinase (MAPK) signalling pathways essential for neuronal survival14,15. This interaction gains particular significance given the established role of MAPK–extracellular signal-regulated kinase (ERK) signalling in activity-dependent protein synthesis during synaptic plasticity16,17. In vivo validation studies confirmed that combinatorial targeting of Mid1 and Syngap1 effectively reversed sevoflurane-induced cognitive impairments18. Collectively, these findings establish a mechanistic link between m6A methylation dynamics and Mid1–Syngap1 signalling in anaesthetic-induced neurotoxicity. The identified pathways provide molecular insights into clinical observations of increased neurodevelopmental risks associated with multiple early-life anaesthetic exposures. This work advances our understanding of anaesthesia-related cognitive dysfunction and highlights potential therapeutic targets for mitigating neurotoxic effects. Materials and methods Ethics statement All experiments were approved by the Zhejiang University Institutional Review Board of Animal Studies (ZJU20210174) and were performed in accordance with the Guidelines and Recommendations for Experimental Animal Care and Use of the Ministry of Science and Technology of China19. Animal model and treatment This study utilized P2 neonatal C57BL/6 mice (Shanghai SLAC Laboratory Animal) due to their favourable neurodevelopmental characteristics. The mice were randomly assigned to either the control (CON) group or the sevoflurane (Sevo) group. On postnatal days 6, 8 and 10, the neonatal C57BL/6 mice were placed in an anaesthesia chamber and exposed to a mixture of 3% sevoflurane and 60% oxygen (balanced with nitrogen) for 2 h. The CON group received the same gas mixture without sevoflurane. This exposure protocol aimed to simulate the clinical conditions of anaesthetic exposure, allowing for the assessment of its cognitive effects in a controlled environment. Methylated RNA immunoprecipitation sequencing Following treatment, hippocampal tissues were harvested from both groups for methylated RNA immunoprecipitation sequencing (MeRIP-seq) analysis. Total RNA was extracted using TRIzol reagent (Thermo Fisher), following the manufacturer’s protocol to ensure high-quality RNA suitable for downstream applications. The MeRIP procedure involved the use of an anti-m6A antibody (CST) to specifically enrich for methylated RNA species. After immunoprecipitation, the enriched RNA was purified, and library preparation was performed to create sequencing libraries. These libraries were subsequently sequenced on a high-throughput sequencing platform, enabling the identification of m6A peaks across the transcriptome. RNA sequencing Total RNA extracted from hippocampal tissues was utilized to construct sequencing libraries. The libraries were prepared according to established protocols, ensuring optimal representation of the transcriptome. Following library preparation, sequencing was conducted using a high-throughput platform, generating comprehensive data on gene expression profiles. The resulting raw sequencing data were subjected to rigorous bioinformatics analysis to identify differentially expressed genes and to analyse the distribution of m6A peaks. Quantitative reverse transcription PCR Quantitative reverse transcription PCR (RT-qPCR) was employed to assess the expression levels of target genes, including Mid1 and Syngap1. Total RNA was extracted from hippocampal tissues or cultured neurons and reverse transcribed to cDNA using a reverse transcriptase kit (TaKaRa). Specific primers were designed for each gene of interest, and RT-qPCR was performed using a TB Green mix (TaKaRa). The relative expression levels were calculated using the ΔΔCt method, normalizing against housekeeping genes such as ACTB. Western blot analysis Protein extracts were prepared from hippocampal tissues or cultured neurons using lysis buffer (Thermo Fisher) containing protease inhibitors. The protein concentration was determined using a bicinchoninic acid (BCA) assay (Thermo Fisher). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). The membranes were blocked with bovine serum albumin (BSA) or non-fat milk and probed with specific primary antibodies against Mid1 (Santa Cruz), Syngap1 (Abcam), Bax, Bcl-2, cleaved caspase 3, phosphorylated p38 (p-p38), phosphorylated ERK1/2 (p-ERK1/2), phosphorylated mitogen-activated protein kinase (p-MEK1/2) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control (CST). After incubation with appropriate secondary antibodies, protein bands were visualized using chemiluminescent detection methods. siRNA transfection To investigate the functional role of specific genes, primary neuronal cells were transfected with small interfering RNAs (siRNAs) targeting Mid1, Alkbh5 or YTHDF2 using Lipo2000 transfection (Thermo Fisher) reagent according to the manufacturer’s instructions. Non-targeting control siRNA was included as a baseline comparison. In addition, to explore the effects of gene overexpression, Mid1 was introduced into neuronal cells using a plasmid construct containing the Mid1 gene. This was also facilitated through a suitable transfection reagent, allowing for the investigation of the biological consequences of Mid1 overexpression in the context of sevoflurane exposure. Plasmids transfection Full-length cDNAs encoding human MID1, SYNGAP1, ubiquitin and the indicated truncation mutants were amplified by PCR and cloned into vectors bearing FLAG, HA, His, Myc or GFP tags. Cells were transfected using Lipofectamine® 3000 (Invitrogen/Thermo Fisher Scientific) according to the manufacturer’s instructions. Dual-luciferase reporter assay and mutagenesis Fragments containing the wild-type or mutant Mid1 3′ UTR were inserted upstream of the psiCHECK-2 dual-luciferase vector. For reporter measurements, cells were co-transfected with the wild-type or mutant Mid1 3′ UTR constructs together with OE-ALKBH5, OE-YTHDF2 or the corresponding empty vector. At 24 h after transfection, firefly and Renilla luciferase activities were quantified using the Dual-Luciferase® Reporter Assay System (Promega) according to the manufacturer’s instructions. Behavioural assessments Behavioural assessments were conducted to evaluate the cognitive effects of sevoflurane exposure. Behavioural assessments were conducted at postnatal days 31–36. The Morris water maze test was employed to assess spatial learning and memory. Mice were trained to locate a submerged platform within a pool of water, and latency to reach the platform was recorded. This test measures cognitive function by evaluating the ability of the mice to remember the location of the platform over repeated trials. In addition, the conditioned fear test was performed to assess memory and anxiety-related behaviours. Mice were subjected to a fear conditioning paradigm, and freezing behaviour was quantified as an indicator of memory retention. These behavioural assays provided critical insights into the cognitive impairments induced by sevoflurane exposure. Immunofluorescence detection Histological analyses were performed to assess neuronal health and proliferation in the hippocampus. The terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) (Thermo Fisher) assay was utilized to detect apoptotic cells within brain sections, allowing for the visualization of DNA fragmentation associated with apoptosis. This technique was crucial for quantifying the extent of neuronal loss following sevoflurane exposure. Furthermore, 5-bromo-2ʹ-deoxyuridine (BrdU) (Thermo Fisher) proliferation assays were conducted to evaluate cellular proliferation. Mice were injected with BrdU prior to tissue collection, and brain sections were processed for immunohistochemical detection of BrdU-positive cells. This analysis provided insights into the effects of sevoflurane on neurogenesis and cellular proliferation in the hippocampus. In addition, double staining for p-p38 and p-MEK1/2 was conducted to assess activation of the MAPK signalling pathway. Sections were incubated with specific antibodies against p-p38 and p-MEK1/2, followed by secondary antibodies conjugated to fluorescent dyes. Images were captured using a fluorescence microscope. Flow cytometry for apoptosis detection Flow cytometry was employed to quantify apoptotic cells in neuronal cultures. Following treatment with sevoflurane and transfection with siRNAs, cells were harvested and stained with Annexin V-FITC and propidium iodide according to the manufacturer’s instructions (Thermo Fisher). The stained cells were analysed using a flow cytometer, allowing for the differentiation between live, early apoptotic, and late apoptotic or necrotic cells. This method provided quantitative assessment of the apoptotic response induced by sevoflurane exposure and the effects of gene knockdown. CHX treatment To investigate the stability of the Syngap1 protein in the context of Mid1 knockdown, cycloheximide (CHX; Seleckchem) was used to inhibit protein synthesis. Neuronal cells were treated with CHX at various time points following transfection with Mid1 siRNA. Protein extracts were collected, and western blot analysis was performed to assess the levels of Syngap1 over time. This experiment enabled the determination of the half-life of Syngap1 and elucidated the role of Mid1 in regulating its stability. RNA pull-down assay To investigate the interaction between Mid1 and YTHDF2, RNA pull-down assays were performed. Biotinylated RNA probes corresponding to the m6A-modified regions of Mid1 mRNA were synthesized and incubated with neuronal cell lysates. Streptavidin beads were used to capture the RNA–protein complexes, which were then analysed by western blot analysis to detect the presence of YTHDF2. This assay provided insights into the binding dynamics between m6A-modified RNA and reader proteins, contributing to the understanding of mRNA regulation. Immunoprecipitation and co-immunoprecipitation To investigate protein–protein interactions, immunoprecipitation and co-immunoprecipitation (Co-IP) assays were performed. Protein extracts from neuronal cells were incubated with specific antibodies against Mid1 or Syngap1, followed by the addition of protein A/G beads (Thermo Fisher) to capture the immune complexes. The precipitated proteins were eluted and analysed by western blot analysis to confirm the presence of target proteins. Co-IP assays were conducted in HEK293T cells co-transfected with Flag-Mid1 and Syngap1 plasmids to validate their interaction. The results from these assays provided valuable insights into the molecular mechanisms underlying the regulation of Syngap1 by Mid1. Lentiviral injection To achieve stable knockdown of target genes in vivo, lentiviral vectors containing short hairpin RNA (shRNA) targeting Mid1 and Syngap1 constructs for Mid1 were prepared. P2 neonatal C57BL/6 mice were subjected to intracranial injection of the lentiviral particles to ensure targeted delivery to the hippocampus. Following recovery, the mice were exposed to sevoflurane, and behavioural assessments were conducted to evaluate the cognitive effects of gene manipulation. This approach enabled examination of the long-term effects of Mid1 modulation on cognitive function in the context of sevoflurane exposure. CCK8 assay Cell viability was assessed using the Cell Counting Kit-8 (CCK8) assay (Dojindo). Primary neuronal cells were seeded in a 96-well plate and treated with sevoflurane or transfected with siRNAs. After the treatment period, CCK8 solution was added to each well, and the cells were incubated for 4 h. The absorbance was measured at 450 nm using a microplate reader. LDH-release assay The lactate dehydrogenase (LDH) release assay (Dojindo) was performed to evaluate cell membrane integrity and cytotoxicity. Following treatment with sevoflurane and transfection with siRNAs, the culture medium was collected, and LDH levels were measured using a commercial LDH assay kit according to the manufacturer’s instructions. The amount of LDH released into the medium was quantified, providing an indication of cell death. Statistical analysis For all experiments, data were collected and analysed using appropriate statistical methods. Experiments were performed in triplicate to ensure reproducibility, and differences between groups were assessed using Student’s t-test or one-way analysis of variance (ANOVA), with a significance threshold set at P <0.05. Statistical analyses were conducted using GraphPad Prism software, allowing for a comprehensive evaluation of the data and validation of the experimental hypotheses. Results Differential m6A modification profiles in hippocampal tissue following sevoflurane exposure To investigate the biological role of m6A modifications in the cognitive functions of young mice subjected to multiple exposures with sevoflurane, MeRIP-seq was performed on hippocampal tissue samples from both the control (CON) and sevoflurane (Sevo) groups. This analysis identified an average of 11,680 m6A peaks in the CON group and 12,094 peaks in the Sevo group. Venn diagram analysis indicated that 1643 peaks were common to both groups (Fig. 1a,b). By comparing m6A methylation levels between the Sevo and CON groups, 2091 differentially methylated m6A peaks were identified in mRNA, of which 1543 were hypermethylated and 548 were hypomethylated (fold change ≥1.0 and false discovery rate <0.05) (Fig. 1c). Further analysis showed that m6A peaks preferentially localized near the CDS and 3′ UTR in both groups, with similar distribution patterns in gene regions. Specifically, the abundance of m6A peaks was notably higher in the 3′ UTR (31.5% in the CON group and 32.4% in the Sevo group), CDS (39.4% and 37.6%, respectively) and stop codon regions (23.7% and 24.1%, respectively) (Fig. 1d,e). In addition, m6A methylation enrichment analysis revealed that the average log2 enrichment ratio was 4.05 in the CON group and 4.32 in the Sevo group (Fig. 1f). Motif analysis characterized the m6A modification profile, identifying the most conserved motif among m6A peaks as GGACU (Fig. 1g). Analysis of the distribution of m6A peaks across individual mRNAs indicated that most mRNAs contained one or two m6A peaks (Fig. 1h). All m6A peaks were mapped to human chromosomes, particularly enriched on chr1, chr2, chr7 and chr11 (Fig. 1i), with dysregulated m6A peaks observed across all chromosomes but especially on chr1, chr2 and chr11 (Fig. 1j). This comprehensive profiling underscores the intricate role of m6A modifications in hippocampal tissue and their potential implications in cognitive function.Fig. 1Differential m6A modification profiles in hippocampal tissue following sevoflurane exposure.Bar chart and Venn diagram showing the overlap of m6A peaks in the control (CON) and sevoflurane (Sevo) groups, with 1,643 peaks common to both groups (parts a and b). Volcano plot of differentially methylated m6A peaks, highlighting 1,543 hypermethylated and 548 hypomethylated peaks (fold change ≥1.0 and false discovery rate <0.05) (part c). Distribution of m6A peaks in genomic regions, including 3′ untranslated region (UTR), coding sequences (CDS) and stop codon regions, for both groups (parts d and e). Violin plot of average log2 enrichment ratios of m6A peaks in the CON (4.05) and Sevo (4.32) groups (part f). Sequence logo of the conserved m6A motif (GGACU) identified in the methylated RNA immunoprecipitation sequencing analysis (part g). Histogram showing the distribution of m6A peaks across individual mRNAs (part h). Histogram of m6A peak localization on human chromosomes, with enrichment on chr1, chr2, chr7 and chr11 (part i). The distribution of differentially methylated m6A peaks in human chromosomes (part j). Differential m6A modification profiles in hippocampal tissue following sevoflurane exposure. Bar chart and Venn diagram showing the overlap of m6A peaks in the control (CON) and sevoflurane (Sevo) groups, with 1,643 peaks common to both groups (parts a and b). Volcano plot of differentially methylated m6A peaks, highlighting 1,543 hypermethylated and 548 hypomethylated peaks (fold change ≥1.0 and false discovery rate <0.05) (part c). Distribution of m6A peaks in genomic regions, including 3′ untranslated region (UTR), coding sequences (CDS) and stop codon regions, for both groups (parts d and e). Violin plot of average log2 enrichment ratios of m6A peaks in the CON (4.05) and Sevo (4.32) groups (part f). Sequence logo of the conserved m6A motif (GGACU) identified in the methylated RNA immunoprecipitation sequencing analysis (part g). Histogram showing the distribution of m6A peaks across individual mRNAs (part h). Histogram of m6A peak localization on human chromosomes, with enrichment on chr1, chr2, chr7 and chr11 (part i). The distribution of differentially methylated m6A peaks in human chromosomes (part j). Combined analysis of m6A sequencing and RNA-seq data reveals a strong correlation between Mid1 and sevoflurane-induced cognitive impairment To further explore the target genes of m6A modifications, a combined analysis of MeRIP-seq and RNA-seq data was conducted, categorizing the 253 differentially methylated m6A peaks with differential RNA levels into four groups. Notably, 194 hypermethylated m6A peaks were significantly upregulated (92; hyper-up) or downregulated (102; hyper-down) in RNA, while 59 hypomethylated m6A peaks exhibited significant upregulation (39; hypo-up) or downregulation (20; hypo-down) (Fig. 2a). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on genes with substantial differences in m6A peaks and synchronized differential expression to elucidate their biological significance. Gene Ontology analysis revealed that these genes were predominantly enriched in biological processes related to mRNA processing and histone modification (BP), thiol-dependent ubiquitin and cadherin binding (MF), as well as adherens junctions and chromosomal regions (CC) (Fig. 2b–d). KEGG pathway analysis indicated that these genes were primarily enriched in the protein processing pathways in the endoplasmic reticulum and ubiquitin-mediated proteolysis (Fig. 2e). To identify potential ubiquitin ligase E3 candidates associated with these differential genes, Venn diagram analysis was performed using the UniProtKB database, which highlighted Mid1 as a potential target gene (Fig. 2f). Further visualization using IGV software showed a marked decrease in m6A methylation of Mid1 mRNA in the Sevo group (Fig. 2g). To ascertain the correlation between Mid1 and cognitive impairment induced by sevoflurane exposure, the expression levels of Mid1 post-exposure were analysed using western blot analysis and RT-qPCR, revealing a significant upregulation of Mid1 (Fig. 2h,i). To determine the cell-type specificity of Mid1 expression in the hippocampus, immunofluorescence staining was performed to examine Mid1 localization in neurons (NeuN⁺), microglia (Iba1⁺) and astrocytes (GFAP⁺); notably, Mid1 was selectively upregulated in NeuN⁺ neurons in the Sevo group, with no obvious increase observed in Iba1⁺ microglia or GFAP⁺ astrocytes (Fig. 2j). These findings suggest that Mid1 may play a critical role in mediating the cognitive deficits associated with sevoflurane exposure.Fig. 2Integrated analysis of m6A sequencing and RNA sequencing data reveals a strong correlation between Mid1 and sevoflurane-induced cognitive impairment.Four-quadrant diagram categorizing 253 differentially methylated m6A peaks based on RNA expression levels (part a). Gene Ontology analysis results indicating enriched biological processes, molecular functions and cellular components among differentially expressed genes (parts b–d). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis illustrating pathways enriched in differentially expressed genes, including protein processing and ubiquitin-mediated proteolysis (part e). Venn diagram identifying Mid1 as a potential target gene through analysis of ubiquitin ligases (part f). Visualization of m6A methylation levels in Mid1 mRNA, showing a decrease in the sevoflurane (Sevo) group (part g). Western blot analysis and quantitative reverse transcription PCR were used to validate the expression levels of Mid1 after exposure to sevoflurane (parts h and i). Co-immunofluorescence staining of hippocampal sections for Mid1 with NeuN (neurons), Iba1 (microglia) and GFAP (astrocytes) to determine cell-type specificity of Mid1 upregulation following sevoflurane exposure (part j). CON, control; IP, immunoprecipitation; MeRIP-seq, methylated RNA immunoprecipitation sequencing; RNA-seq, RNA sequencing. Integrated analysis of m6A sequencing and RNA sequencing data reveals a strong correlation between Mid1 and sevoflurane-induced cognitive impairment. Four-quadrant diagram categorizing 253 differentially methylated m6A peaks based on RNA expression levels (part a). Gene Ontology analysis results indicating enriched biological processes, molecular functions and cellular components among differentially expressed genes (parts b–d). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis illustrating pathways enriched in differentially expressed genes, including protein processing and ubiquitin-mediated proteolysis (part e). Venn diagram identifying Mid1 as a potential target gene through analysis of ubiquitin ligases (part f). Visualization of m6A methylation levels in Mid1 mRNA, showing a decrease in the sevoflurane (Sevo) group (part g). Western blot analysis and quantitative reverse transcription PCR were used to validate the expression levels of Mid1 after exposure to sevoflurane (parts h and i). Co-immunofluorescence staining of hippocampal sections for Mid1 with NeuN (neurons), Iba1 (microglia) and GFAP (astrocytes) to determine cell-type specificity of Mid1 upregulation following sevoflurane exposure (part j). CON, control; IP, immunoprecipitation; MeRIP-seq, methylated RNA immunoprecipitation sequencing; RNA-seq, RNA sequencing. Inhibition of Mid1 improves cognitive dysfunction induced by sevoflurane exposure Various behavioural and histological assessments were employed to evaluate the role of Mid1 in ameliorating cognitive dysfunction in young mice exposed to sevoflurane. Results from the water maze experiment demonstrated that knockdown of Mid1 significantly alleviated the prolonged latency period (Fig. 3a,b). Similarly, in the conditioned fear test, Mid1 knockdown mice exhibited improved freezing behaviour, indicating a restoration of memory and anxiety responses impaired by sevoflurane (Fig. 3c,d). Histological analyses further supported these behavioural findings; TUNEL assays revealed that Mid1 knockdown effectively reduced the sevoflurane-induced apoptosis of hippocampal neurons (Fig. 3e). In addition, in vitro experiments were conducted to validate the impact of Mid1 on sevoflurane-induced neurotoxicity. Primary neuronal cells were transfected with non-coding siRNA and Mid1 siRNA and subsequently subjected to sevoflurane exposure. CCK8 assays indicated a significant increase in cell viability in the Mid1 siRNA group compared with the non-coding siRNA group, suggesting that Mid1 knockdown mitigated the cytotoxic effects of sevoflurane (Fig. 3f). LDH-release assays demonstrated that LDH levels in the Mid1 siRNA group post-sevoflurane treatment were significantly lower than those in the non-coding siRNA group (Fig. 3g). Flow cytometry analysis revealed a marked reduction in apoptosis levels in the Mid1 siRNA group following sevoflurane treatment (Fig. 3h). Western blot analysis showed that the levels of Bax and cleaved caspase 3 proteins were significantly decreased, while Bcl-2 levels were notably increased in the Mid1 siRNA group after sevoflurane treatment (Fig. 3i). These findings collectively suggest that Mid1 knockdown significantly alleviates sevoflurane-induced neurotoxicity, underscoring its pivotal role in preventing cognitive deficits and neuronal damage.Fig. 3Inhibition of Mid1 ameliorates cognitive dysfunction induced by sevoflurane exposure.Morris water maze results demonstrating reduced latency to reach the platform following Mid1 knockdown (parts a and b). Conditioned fear test data indicating improved freezing behaviour in Mid1 knockdown mice (parts c and d). TUNEL assay images showing reduced apoptosis in hippocampal neurons with Mid1 knockdown (part e). The Cell Counting Kit-8 assay was used to validate the effect of Mid1 knockdown on the proliferation of neuronal cells in the presence of sevoflurane (sevo; part f). The lactate dehydrogenase (LDH) assay was conducted to assess the toxic effects of Mid1 knockdown on neuronal cells in the presence of sevoflurane (part g). Flow cytometry and western blot analysis were employed to validate the effect of Mid1 knockdown on the apoptosis of neuronal cells in the presence of sevoflurane (parts h and i). CON, control; NC, non-coding; PI, propidium iodide; shRNA, short hairpin RNA; siRNA, small interfering RNA. Inhibition of Mid1 ameliorates cognitive dysfunction induced by sevoflurane exposure. Morris water maze results demonstrating reduced latency to reach the platform following Mid1 knockdown (parts a and b). Conditioned fear test data indicating improved freezing behaviour in Mid1 knockdown mice (parts c and d). TUNEL assay images showing reduced apoptosis in hippocampal neurons with Mid1 knockdown (part e). The Cell Counting Kit-8 assay was used to validate the effect of Mid1 knockdown on the proliferation of neuronal cells in the presence of sevoflurane (sevo; part f). The lactate dehydrogenase (LDH) assay was conducted to assess the toxic effects of Mid1 knockdown on neuronal cells in the presence of sevoflurane (part g). Flow cytometry and western blot analysis were employed to validate the effect of Mid1 knockdown on the apoptosis of neuronal cells in the presence of sevoflurane (parts h and i). CON, control; NC, non-coding; PI, propidium iodide; shRNA, short hairpin RNA; siRNA, small interfering RNA. ALKBH5 and YTHDF2 regulate Mid1 expression through m6A modifications and influence sevoflurane-induced cognitive impairment The overall m6A levels in hippocampal tissue before and after sevoflurane exposure were compared, with quantitative analysis and dot blot results indicating a significant reduction in overall m6A levels in the Sevo group (Fig. 4a). A similar trend was observed in primary neuronal cells (Fig. 4b). Using the SRAMP tool (http://www.Cuilab.cn/sramp), the m6A modification sites within the Mid1 mRNA sequence were analysed and several high-confidence m6A modification sites were identified (Fig. 4c). MeRIP-PCR analysis was conducted to further validate the m6A modifications of Mid1, demonstrating significant enrichment of Mid1 in both the CON and Sevo groups, with lower levels observed in the Sevo group than in the CON group (Fig. 4d). m6A is a reversible RNA modification, regulated by m6A methyltransferases and demethylases. Analysis of m6A-related enzyme expression in RNA-seq data before and after sevoflurane exposure revealed a significant upregulation of the demethylase ALKBH5 (P = 0.0097) (Fig. 4e). RT-qPCR and western blot analyses confirmed that ALKBH5 levels were significantly elevated following sevoflurane exposure (Fig. 4f). Notably, siRNA-mediated knockdown of Alkbh5 in neuronal cells led to a significant decrease in Mid1 expression (Fig. 4g). Thus, it can be concluded that the m6A modification of Mid1 is regulated by ALKBH5. Previous studies have shown that, when m6A in mRNAs is recognized by reader proteins such as YTHDF, YTHDC and HNRNPA2B1, it can promote mRNA decay or translation. In the present experiments, RNA pull-down assays revealed that Mid1 could significantly bind to the reader protein YTHDF2 (Fig. 4h). RNA immunoprecipitation followed by qPCR (RIP-qPCR) further confirmed the interaction between YTHDF2 and Mid1, showing significant enrichment of Mid1 RNA in neuronal cells compared with the control IgG group (Fig. 4i). To determine whether YTHDF2 affects Mid1 expression, YTHDF2 in neuronal cells were knocked down, resulting in upregulation of Mid1 at both RNA and protein levels (Fig. 4j). In addition, the impact of YTHDF2 on the stability of Mid1 RNA was analysed. Following transfection with YTHDF2 siRNA and non-coding siRNA, total RNA was harvested at various time points after treatment with actinomycin D. The absence of YTHDF2 significantly enhanced the stability of Mid1 RNA (Fig. 4k). In summary, ALKBH5 and YTHDF2 regulate Mid1 expression through m6A modifications, highlighting their critical roles in cognitive impairment induced by sevoflurane. To determine whether ALKBH5 regulates Mid1 expression via m⁶A modification, the Mid1 mRNA sequence was analysed and the SRAMP predictor was used to identify DRACH motifs within the 3′ UTR (D = A/G/U; R = purine; H = A/C/U). Either the wild-type Mid1 3′ UTR or an m⁶A-deficient 3′ UTR (A to T substitutions at the predicted motifs) was then cloned into dual-luciferase reporters (Fig. 4l) and the reporter activity in transfected HEK293T cells was measured. Alkbh5 overexpression led to a significant increase in luciferase activity for the wild-type 3′ UTR reporter, whereas the mutant 3′ UTR reporter showed no appreciable change (Fig. 4m). Conversely, YTHDF2 overexpression reduced the wild-type reporter signal but had minimal effect on the mutant (Fig. 4n). These findings indicate that intact m⁶A sites are required for ALKBH5-mediated stabilization, consistent with a YTHDF2-dependent post-transcriptional decay mechanism.Fig. 4ALKBH5 and YTHDF2 regulate Mid1 expression through m6A modifications.a, Overall m6A levels in hippocampal tissues from control (CON) and sevoflurane (Sevo) groups. b, Similar results for primary neuronal cells, indicating decreased m6A levels after sevoflurane exposure. c, Identification of high-confidence m6A modification sites within the Mid1 mRNA sequence. d, Methylated RNA immunoprecipitation PCR analysis confirming Mid1 enrichment, with lower levels in the Sevo group. e, Expression levels of m6A-related enzymes, highlighting upregulation of Alkbh5 after sevoflurane exposure. f, Validation of increased ALKBH5 levels post-exposure using quantitative reverse transcription PCR and western blot analysis. g, Impact of Alkbh5 knockdown on Mid1 expression. h, RNA pull-down assays were performed to analyse the binding of Mid1 to reader proteins. i, RIP-qPCR was conducted to validate the interaction between YTHDF2 and Mid1. j, The impact of YTHDF2 knockdown on Mid1 expression was assessed. k, Actinomycin D experiments were carried out to examine the stability of Mid1 mRNA following YTHDF2 knockdown. l, Online prediction of candidate m6A motifs in the Mid1 3′ untranslated region (UTR) using SRAMP; luciferase reporter constructs bearing the mouse Mid1 3′ UTR with intact m6A motifs or site-directed A to T mutations. m, Relative luciferase activity in HEK293T cells co-transfected with plasmids carrying wild-type (WT) or mutant (Mut) Mid1 3′ UTR and either OE-ALKBH5 or control vector. n, Relative luciferase activity in HEK293T cells co-transfected with plasmids carrying WT or mutant Mid1 3′ UTR and either OE-YTHDF2 or control vector. o, The Cell Counting Kit-8 assay was used to evaluate the proliferation of neuronal cells in rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. p, The lactate dehydrogenase (LDH) assay was performed to assess the toxic effects on neuronal cells in rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. q, Flow cytometry was used to detect apoptosis in neuronal cells during rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. NC, non-coding; PI, propidium iodide; siRNA, small interfering RNA. ALKBH5 and YTHDF2 regulate Mid1 expression through m6A modifications. a, Overall m6A levels in hippocampal tissues from control (CON) and sevoflurane (Sevo) groups. b, Similar results for primary neuronal cells, indicating decreased m6A levels after sevoflurane exposure. c, Identification of high-confidence m6A modification sites within the Mid1 mRNA sequence. d, Methylated RNA immunoprecipitation PCR analysis confirming Mid1 enrichment, with lower levels in the Sevo group. e, Expression levels of m6A-related enzymes, highlighting upregulation of Alkbh5 after sevoflurane exposure. f, Validation of increased ALKBH5 levels post-exposure using quantitative reverse transcription PCR and western blot analysis. g, Impact of Alkbh5 knockdown on Mid1 expression. h, RNA pull-down assays were performed to analyse the binding of Mid1 to reader proteins. i, RIP-qPCR was conducted to validate the interaction between YTHDF2 and Mid1. j, The impact of YTHDF2 knockdown on Mid1 expression was assessed. k, Actinomycin D experiments were carried out to examine the stability of Mid1 mRNA following YTHDF2 knockdown. l, Online prediction of candidate m6A motifs in the Mid1 3′ untranslated region (UTR) using SRAMP; luciferase reporter constructs bearing the mouse Mid1 3′ UTR with intact m6A motifs or site-directed A to T mutations. m, Relative luciferase activity in HEK293T cells co-transfected with plasmids carrying wild-type (WT) or mutant (Mut) Mid1 3′ UTR and either OE-ALKBH5 or control vector. n, Relative luciferase activity in HEK293T cells co-transfected with plasmids carrying WT or mutant Mid1 3′ UTR and either OE-YTHDF2 or control vector. o, The Cell Counting Kit-8 assay was used to evaluate the proliferation of neuronal cells in rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. p, The lactate dehydrogenase (LDH) assay was performed to assess the toxic effects on neuronal cells in rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. q, Flow cytometry was used to detect apoptosis in neuronal cells during rescue experiments involving Alkbh5 knockdown and Mid1 overexpression. NC, non-coding; PI, propidium iodide; siRNA, small interfering RNA. Furthermore, the effect of Alkbh5-mediated regulation of Mid1 expression on sevoflurane-induced neurotoxicity in vitro was validated. Alkbh5 siRNA was transfected while simultaneously overexpressing Mid1 in primary neuronal cells for rescue experiments, followed by sevoflurane exposure. CCK8 assays indicated that cell viability in the Alkbh5 siRNA group was significantly higher than in the non-coding siRNA group. However, cell viability in the Alkbh5 siRNA group combined with Mid1 overexpression was significantly reduced compared with the Alkbh5 siRNA group alone, indicating that Mid1 overexpression reversed the alleviation of sevoflurane-induced cytotoxicity observed with Alkbh5 knockdown (Fig. 4o). LDH-release assays revealed that LDH levels in the Alkbh5 siRNA group following sevoflurane treatment were significantly lower than those in the non-coding siRNA group, while LDH levels in the Alkbh5 siRNA group combined with Mid1 overexpression were significantly elevated compared with the Alkbh5 siRNA group (Fig. 4p). Flow cytometry analysis showed that the Alkbh5 siRNA group significantly reduced apoptosis levels following sevoflurane treatment, while Alkbh5 siRNA combined with Mid1 overexpression reversed this effect (Fig. 4q). Overall, m6A modifications regulating Mid1 expression play a crucial role in sevoflurane-induced cognitive impairment. Mid1 regulates the ubiquitination process of Syngap1 To elucidate the molecular mechanisms by which Mid1 contributes to sevoflurane-induced cognitive impairment, proteins interacting with Mid1 were identified through mass spectrometry and immunoprecipitation analysis, listing the top five differential proteins. Using the UbiBrowser database (http://ubibrowser.bio-it.cn/ubibrowser/), it was validated that differential proteins potentially bind to ubiquitin E3 ligases, with Syngap1 predicted as a substrate of Mid1 (Fig. 5a,b). Silver staining revealed a specific protein band for Syngap1 in the Mid1 immunoprecipitation group compared with the IgG group (Fig. 5c). To further explore the interaction between Mid1 and Syngap1, Co-IP assays were performed using anti-Mid1 and anti-Syngap1 antibodies in neuronal cells, confirming their endogenous interaction (Fig. 5d). In addition, Co-IP assays conducted in HEK293T cells co-transfected with Flag-Mid1 and Syngap1 plasmids further validated their interaction (Fig. 5e). Notably, these experiments demonstrated that knockdown of Mid1 expression in neuronal cells did not affect Syngap1 mRNA levels but led to a significant increase in Syngap1 protein levels (Fig. 5f,g), indicating a post-transcriptional regulatory mechanism. To elucidate the regulatory mechanism by which Mid1 influences Syngap1 stability, CHX treatment was employed to block protein translation; western blot analysis showed a significantly prolonged half-life of Syngap1 in Mid1 knockdown cells (Fig. 5h). Furthermore, a marked downregulation of ubiquitinated Syngap1 levels following Mid1 knockdown was observed (Fig. 5i). To define the chain type responsive to Mid1-mediated ubiquitination of Syngap1, Mid1, Syngap1 and chain-restricted ubiquitin variants (K6/K11/K29/K33/K48/K63) were co-expressedin HEK293T cells. Only K48-linked polyubiquitination was markedly increased in the presence of Mid1 (Fig. 5j). Consistently, transfection with the ubiquitin K48R mutant significantly abolished both Mid1 overexpression-induced downregulation of Syngap1 protein and the increase in Syngap1 ubiquitination (Fig. 5k,l). To further pinpoint the Syngap1 ubiquitination site responsible for Mid1-induced modification, the iPTMnet database was used to design nine Syngap1 mutants in which lysine (K) residues were substituted with arginine (R), and each mutant was co-transfected with Flag-Mid1 and His-tagged K48-only ubiquitin into HEK293T cells. Only the K710R mutant was found to significantly abrogate the ubiquitination level (Fig. 5m). Under protein-synthesis blockade (CHX treatment), Mid1 no longer reduced K710R protein levels (Fig. 5n), supporting K710 as a functional acceptor lysine. Collectively, these findings underscore the pivotal role of Mid1 in regulating Syngap1 stability through ubiquitin-mediated degradation, revealing a potential mechanism of neurotoxicity in the neuronal environment.Fig. 5Mid1 regulates the ubiquitination process of Syngap1.Identification of proteins interacting with Mid1 using mass spectrometry (parts a and b). Silver staining showing specific bands for Syngap1 in the Mid1 immunoprecipitation group (part c). Co-immunoprecipitation (Co-IP) assay confirming Mid1 and Syngap1 interaction in neuronal cells (part d). Validation of interaction in HEK293T cells co-transfected with Flag-Mid1 and Syngap1 (part e). Analysis of Syngap1 protein levels following Mid1 knockdown (parts f and g). Western blot analysis showing Syngap1 half-life in Mid1 knockdown cells after cycloheximide (CHX) treatment (part h). Levels of ubiquitinated Syngap1 following Mid1 knockdown (part i). HEK293T cells co-transfected with Flag-Mid1, Myc-Syngap1 and the indicated His-Ub plasmids; assessment of Myc-Syngap1 ubiquitination (part j). Co-IP analysis of HEK293T cells expressing Myc-Syngap1 and His-ubiquitin (K48 or K48R) with or without Flag-Mid1 (part k). Lysate analysis of HEK293T cells co-expressing Flag-Mid1 and Myc-Syngap1 and transfected with K48 or K48R Ub; quantification by immunoblotting (part l). Co-IP analysis of HEK293T cells transfected with His-Ub, Flag-Mid1, and Myc-Syngap1 or the indicated mutants (part m). Immunoblotting of lysates from HEK293T cells co-transfected with Myc-tagged Syngap1 (wild-type (WT) or K710R) and Flag-Mid1, with or without CHX (10 μg/ml), using anti-Flag and anti-Myc antibodies at the indicated time points (part n). NC, non-coding; siRNA, small interfering RNA. Mid1 regulates the ubiquitination process of Syngap1. Identification of proteins interacting with Mid1 using mass spectrometry (parts a and b). Silver staining showing specific bands for Syngap1 in the Mid1 immunoprecipitation group (part c). Co-immunoprecipitation (Co-IP) assay confirming Mid1 and Syngap1 interaction in neuronal cells (part d). Validation of interaction in HEK293T cells co-transfected with Flag-Mid1 and Syngap1 (part e). Analysis of Syngap1 protein levels following Mid1 knockdown (parts f and g). Western blot analysis showing Syngap1 half-life in Mid1 knockdown cells after cycloheximide (CHX) treatment (part h). Levels of ubiquitinated Syngap1 following Mid1 knockdown (part i). HEK293T cells co-transfected with Flag-Mid1, Myc-Syngap1 and the indicated His-Ub plasmids; assessment of Myc-Syngap1 ubiquitination (part j). Co-IP analysis of HEK293T cells expressing Myc-Syngap1 and His-ubiquitin (K48 or K48R) with or without Flag-Mid1 (part k). Lysate analysis of HEK293T cells co-expressing Flag-Mid1 and Myc-Syngap1 and transfected with K48 or K48R Ub; quantification by immunoblotting (part l). Co-IP analysis of HEK293T cells transfected with His-Ub, Flag-Mid1, and Myc-Syngap1 or the indicated mutants (part m). Immunoblotting of lysates from HEK293T cells co-transfected with Myc-tagged Syngap1 (wild-type (WT) or K710R) and Flag-Mid1, with or without CHX (10 μg/ml), using anti-Flag and anti-Myc antibodies at the indicated time points (part n). NC, non-coding; siRNA, small interfering RNA. Mid1 mediates the MAPK signalling pathway through regulation of Syngap1 in sevoflurane-induced cognitive impairment To directly assess the sufficiency of Mid1, Mid1 was overexpressed in primary neurons under sevoflurane-free conditions. Mid1 overexpression markedly decreased Syngap1 protein levels and concomitantly activated the MAPK pathway (Fig. 6a). Reduced cell viability, elevated LDH release and increased apoptosis were also observed (Fig. 6b–d). To investigate the role of Mid1 in regulating Syngap1 and its implications in sevoflurane-induced neurotoxicity, rescue experiments were conducted by transfecting neuronal cells with Mid1 siRNA, Syngap1 siRNA and a combination of both, followed by sevoflurane exposure. CCK8 assays indicated that cell viability in the co-transfection group was significantly lower than viability in the Mid1 siRNA group, while the co-transfection group exhibited significantly higher cell viability than the Syngap1 siRNA group, suggesting that Syngap1 knockdown partially reversed the cytotoxic effects of sevoflurane seen with Mid1 knockdown (Fig. 6e). LDH-release assays demonstrated that LDH levels in the co-transfection group were significantly elevated compared with levels in the Mid1 siRNA group, while the levels were significantly reduced compared with those in the Syngap1 siRNA group (Fig. 6f). Flow cytometry analysis revealed that apoptosis levels in the co-transfection group were significantly higher than levels in the Mid1 siRNA group, while the co-transfection group exhibited significantly lower cell apoptosis than the Syngap1 siRNA group (Fig. 6g). Western blot analysis indicated that the levels of Bax and cleaved caspase 3 proteins were significantly elevated in the co-transfection group compared with the Mid1 siRNA group, while Bcl-2 levels were notably decreased; conversely, the co-transfection group exhibited decreased levels of Bax and cleaved caspase 3 proteins and increased Bcl-2 levels compared with the Syngap1 siRNA group (Fig. 6h). Compared with the non-coding siRNA group, phosphorylation levels of P38, ERK1/2 and MEK1/2 were significantly reduced in the Mid1 siRNA group, while phosphorylation levels of P38, ERK1/2 and MEK1/2 were significantly increased in the Syngap1 siRNA group. In contrast to the Mid1 siRNA group, the co-transfection group reversed the downregulation of phosphorylation levels of P38, ERK1/2 and MEK1/2; conversely, compared with the Syngap1 siRNA group, the co-transfection group reversed the increase in phosphorylation levels of P38, ERK1/2 and MEK1/2 (Fig. 6i). Additionally, complementary gain-of-function experiments were performed by overexpressing Syngap1. In primary neurons exposed to sevoflurane, Syngap1 overexpression significantly attenuated the injury phenotype, restoring cell proliferation, lowering LDH release and reducing apoptosis (Fig. 6j–l). These findings suggest that Mid1 regulates Syngap1, which mediates the MAPK signalling pathway, playing a crucial role in the cognitive impairment induced by sevoflurane.Fig. 6Mid1 mediates the MAPK signalling pathway through regulation of Syngap1.Western blot analysis of Syngap1 protein and MAPK pathway activation markers in neurons overexpressing Mid1 (part a). Cell Counting Kit-8 (CCK8) assay results demonstrating cell viability in neurons overexpressing Mid1 (part b). Lactate dehydrogenase (LDH) release assay quantifying cell death of neurons overexpressing Mid1 (part c). Apoptosis quantified by an apoptosis assay (part d). CCK8 assay results demonstrating cell viability in co-transfected neuronal cells after sevoflurane (Sevo) exposure (part e). LDH-release assay quantifying cell death in response to Sevo treatment (part f). Flow cytometry and western blot analysis showing apoptosis levels in neuronal cultures (parts g and h). Western blot analysis of the activation status of the MAPK signalling pathway (part i). CCK8 assay showing cell viability in Syngap1-overexpressing neurons after Sevo exposure (part j). LDH-release assay quantifying cell death in Syngap1-overexpressing neurons in response to sevoflurane (part k). Flow cytometry measuring apoptosis in neuronal cultures overexpressing Syngap1 after Sevo treatment (part l). NC, non-coding; PI, propidium iodide; siRNA, small interfering RNA. Mid1 mediates the MAPK signalling pathway through regulation of Syngap1. Western blot analysis of Syngap1 protein and MAPK pathway activation markers in neurons overexpressing Mid1 (part a). Cell Counting Kit-8 (CCK8) assay results demonstrating cell viability in neurons overexpressing Mid1 (part b). Lactate dehydrogenase (LDH) release assay quantifying cell death of neurons overexpressing Mid1 (part c). Apoptosis quantified by an apoptosis assay (part d). CCK8 assay results demonstrating cell viability in co-transfected neuronal cells after sevoflurane (Sevo) exposure (part e). LDH-release assay quantifying cell death in response to Sevo treatment (part f). Flow cytometry and western blot analysis showing apoptosis levels in neuronal cultures (parts g and h). Western blot analysis of the activation status of the MAPK signalling pathway (part i). CCK8 assay showing cell viability in Syngap1-overexpressing neurons after Sevo exposure (part j). LDH-release assay quantifying cell death in Syngap1-overexpressing neurons in response to sevoflurane (part k). Flow cytometry measuring apoptosis in neuronal cultures overexpressing Syngap1 after Sevo treatment (part l). NC, non-coding; PI, propidium iodide; siRNA, small interfering RNA. In vivo study of the role of Mid1 in regulating Syngap1 in sevoflurane-induced cognitive impairment To determine whether Mid1 mediates sevoflurane-induced neurotoxicity through the regulation of Syngap1 in vivo, P2 neonatal C57BL/6 mice were intracranially injected with non-coding shRNA, Mid1 shRNA, Syngap1 shRNA, and a combination of Mid1 shRNA and Syngap1 shRNA. Subsequently, the neuroprotective effects of Mid1 and Syngap1 in the sevoflurane-exposed mouse model were assessed through behavioural and histological evaluations. The results from the water maze experiment indicated that the combination group showed a reversal in the latency decrease induced by Mid1 shRNA and the latency increase caused by Syngap1 shRNA (Fig. 7a,b). Similarly, in the conditioned fear test, the combination group showed a reversal in the increased freezing behaviour induced by Mid1 shRNA and the decreased freezing behaviour caused by Syngap1 shRNA (Fig. 7c,d). Histological analyses further demonstrated that BrdU proliferation staining indicated a reversal of the increased proliferation caused by Mid1 shRNA and the decreased proliferation induced by Syngap1 shRNA in the combination group (Fig. 7e,f). In addition, TUNEL assays revealed that the combination group showed a reversal in the reduction in hippocampal neuronal apoptosis induced by Mid1 shRNA and the increase in apoptosis caused by Syngap1 shRNA (Fig. 7g,h). These results provide compelling evidence that Mid1 promotes neurotoxicity and cognitive impairment following sevoflurane exposure through the regulation of Syngap1.Fig. 7In vivo investigation of the role of Mid1 in regulating Syngap1 in sevoflurane-induced cognitive impairment.The water maze test showed changes in escape latency (parts a and b). The contextual fear conditioning test revealed variations in freezing time (parts c and d). Histological analysis of BrdU in brain sections was used to assess the proliferation of hippocampal neurons (parts e and f). Histological analysis of TUNEL staining in brain sections evaluated the apoptosis of hippocampal neurons (parts g and h). NC, non-coding; shRNA, short hairpin RNA. In vivo investigation of the role of Mid1 in regulating Syngap1 in sevoflurane-induced cognitive impairment. The water maze test showed changes in escape latency (parts a and b). The contextual fear conditioning test revealed variations in freezing time (parts c and d). Histological analysis of BrdU in brain sections was used to assess the proliferation of hippocampal neurons (parts e and f). Histological analysis of TUNEL staining in brain sections evaluated the apoptosis of hippocampal neurons (parts g and h). NC, non-coding; shRNA, short hairpin RNA. Discussion Research into the cognitive effects of sevoflurane exposure, particularly during the early developmental stages in young individuals, is increasingly relevant due to the implications for long-term neurodevelopmental outcomes20–22. Cognitive impairments associated with anaesthetic exposure during critical periods of brain development can lead to significant deficits in learning and memory, which have been documented in various animal models23,24. For instance, studies have shown that sevoflurane can induce neuroinflammation and neuronal apoptosis in neonatal rodents, subsequently affecting their cognitive functions later in life25–27. Furthermore, the mechanisms underlying these impairments, including the roles of protein modifications such as m6A methylation and ubiquitination, are not fully understood but are critical for elucidating the pathways that contribute to anaesthetic-induced neurotoxicity10,28–31. In this study, the molecular mechanisms linking sevoflurane exposure to cognitive deficits in neonatal mice were investigated, particularly focusing on the roles of m6A modifications and the ubiquitin–proteasome system. These findings provide insights into how the regulation of key genes, such as Mid1 and Syngap1, intersects with cognitive function and synaptic integrity during anaesthetic exposure32. The research highlights the importance of understanding these molecular pathways as they may pave the way for the development of targeted therapeutic strategies to mitigate cognitive decline associated with surgical anaesthetics33. Investigating the cognitive effects of sevoflurane exposure in neonatal mice reveals significant insights into the molecular mechanisms and signalling pathways involved in anaesthetic-induced neurotoxicity. This study demonstrates that Mid1, a critical E3 ubiquitin ligase, plays a pivotal role in regulating the stability of Syngap1, a protein integral to synaptic plasticity. The findings indicate that the knockdown of Mid1 leads to increased levels of Syngap1 protein without altering its mRNA expression, suggesting that the regulation occurs at a post-transcriptional level through ubiquitin-mediated degradation13,34–36. This discovery elucidates a previously unrecognized mechanism whereby Mid1 influences cognitive outcomes following anaesthetic exposure, thereby highlighting its potential as a therapeutic target for the prevention of cognitive decline associated with sevoflurane anaesthesia. Such insights could inform the development of strategies aimed at mitigating the long-term neurodevelopmental consequences of anaesthetics, reinforcing the significance of understanding these molecular interactions in the context of paediatric anaesthesia. Furthermore, these results reveal the involvement of the MAPK signalling pathway in cognitive impairment induced by sevoflurane37. The regulation of Syngap1 by Mid1 impacts the phosphorylation levels of key components within the MAPK pathway, including p38 and MEK1/2. Understanding this signalling axis is crucial, as it identifies critical nodes for potential pharmacological intervention that could reverse cognitive deficits following anaesthetic exposure. Targeting this pathway may provide new avenues for therapeutic development, offering hope for children at risk of neurodevelopmental disorders due to anaesthetic exposure. Therefore, these findings not only contribute to the existing body of knowledge regarding anaesthetic neurotoxicity but also pave the way for innovative strategies aimed at safeguarding cognitive function during critical periods of brain development. In addition to elucidating the molecular mechanisms, this study highlights the functional implications of Mid1 and Syngap1 on cognitive behaviour in sevoflurane-exposed mice. Behavioural assessments indicated that Mid1 knockdown led to significant improvements in cognitive functions, as demonstrated by enhanced performance in the Morris water maze and conditioned fear tests. These results correlate molecular mechanisms with observable behaviours, underscoring the relevance of Mid1 in cognitive health. The demonstrated potential for behavioural interventions targeting cognitive impairments offers promise for clinical applications, emphasizing the importance of further research into the relationship between molecular targets and cognitive outcomes. This work contributes to a greater understanding of the intricate interplay between anaesthetic exposure, cognitive function and the underlying molecular pathways, ultimately aiming to improve anaesthetic safety in paediatric populations. The limitations of this study should be acknowledged to contextualize the findings within the broader scope of cognitive impairment research. First, while the use of an animal model provides valuable insights, the translational relevance to humans remains uncertain due to inherent biological differences. In addition, the sample size utilized in the experiments may limit the generalizability of the results, warranting further validation through larger-scale studies. Furthermore, the absence of longitudinal assessments restricts understanding of the long-term cognitive outcomes following sevoflurane exposure, leaving potential chronic effects unexplored. Finally, although the molecular mechanisms involving Mid1 and Syngap1 have been elucidated, the complexity of neurodevelopmental processes requires caution when extrapolating these findings to multifactorial conditions such as paediatric anaesthesia neurotoxicity. In conclusion, this research highlights the critical role of Mid1 in mediating the cognitive dysfunction associated with sevoflurane exposure through mechanisms involving m6A modifications and the regulation of Syngap1. The findings provide a framework for understanding the molecular underpinnings of anaesthetic-induced neurotoxicity, suggesting potential avenues for therapeutic interventions aimed at mitigating cognitive deficits. By elucidating the interplay between m6A modifications and ubiquitination in neurodevelopment, this study paves the way for future investigations that may lead to novel strategies to enhance anaesthetic safety in paediatric populations, ultimately contributing to improved long-term cognitive health outcomes.